PDCD1 and cancer: In addition, our results highlight the prominent role of other surface receptors of CTLs and NK cells, such as TIGIT and CTLA-4, as actionable co-inhibitory signals beyond PD-1 in advanced/high-risk cSCCs enriched in hybrid E/M and mesenchymal cancer cells.